Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Shari Germscheid (NPI 1962485680)

Field	Value
Entity Type	Individual
Organization	Shari Germscheid
Address	6320 Wedgewood Rd N
City	Maple Grove
State	MN
ZIP	55311
Taxonomy	Family Nurse Practitioner
NPI Enumerated	November 28, 2005

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider’s Medicare business is the clear revenue driver: lifetime Medicare revenue is $1.4M while Medicaid billing is listed as none, so the provider effectively operates as a single‑payer Medicare biller rather than a dual‑payer practice. The lack of Medicaid activity means any payer‑mix risk or contract strategy should be evaluated primarily through the Medicare lens.

Revenue is highly concentrated in a small set of infused biologic drugs: the precomputed top three Medicare codes account for 75.4% of total Medicare revenue, led by J9271 at $576.8K (41.7%) and J1561 at $394.7K (28.5%), with J1745 contributing $73K (5.3%). This concentration indicates financial dependence on a handful of high‑cost injectable therapies.

The CPT/HCPCS mix suggests an infusion‑centric practice with oncology/immunology and biologic therapy emphasis: J9271 (pembrolizumab), J1561 (immune globulin), and J1745 (infliximab) dominate revenue, and multiple chemotherapy and infusion administration codes (for example 96413, 96365 and add‑on infusion codes) are present. Together, the drug and administration codes are consistent with a workflow built around repeated, high‑volume outpatient infusion sessions.

Competitive standing varies by drug: J1561 ranks #30 of 180 nationally (84th percentile), indicating this provider is a relatively high‑volume national participant for that immune globulin product, while J9271 ranks #803 of 1841 (56th percentile) and J1745 ranks #677 of 1352 (50th percentile), both described as typical or unremarkable volumes. In short, the practice is a major player for selected products but a modest/typical participant for others.

Several administration and support codes post high percentile rankings, reinforcing an infusion‑center operational footprint: 96413 ranks in the 90th percentile (#753 of 7514), 96365 is at the 94th percentile (#515 of 8873), and 96372 is at the 93rd percentile (#4284 of 58224). Additionally, J3489 (zoledronic acid) is flagged as notably above typical national volume at the 96th percentile, representing a statistical outlier among the provider’s otherwise typical code volumes.

There are high claim counts with very low per‑claim payments on some items that hint at low unit reimbursement or pass‑through style billing patterns: J1439 shows 22.5K claims at $1 avg paid/claim ($22.5K revenue) and J0881 shows 5.5K claims at $2 avg paid/claim ($11K revenue). These patterns suggest multiple low‑unit items are billed frequently, which can materially affect administrative workload and reporting despite modest aggregate revenue.

The provider has a long billing tenure: NPI enumerated 2005-11-28 (~21 years ago), indicating an established presence in Medicare billing and likely operational stability in infusion services over multiple regulatory and reimbursement cycles. Long enumeration supports interpreting current patterns as persistent business choices rather than short‑term anomalies.

Given the near‑absence of Medicaid activity (none on file) and the heavy reliance on a few high‑revenue biologic codes, contractual negotiations, reimbursement pressure on specific drugs (especially J9271 and J1561), and supplier relationships for infused products are likely the most consequential business risks and levers for this provider’s revenue trajectory. Analysts should prioritize monitoring those product lines and related administration codes when assessing financial and operational exposure.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,420	$40	$576.8K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	10,390	$40	$394.7K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	2,920	$30	$73K
J0897	Injection, denosumab, 1 mg	3,840	$20	$69.1K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,070	$30	$68.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$90	$43K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	290	$90	$25.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	210	$110	$22.7K
J1439	Injection, ferric carboxymaltose, 1 mg	22,500	$1	$22.5K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	430	$40	$18.5K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Shari Germscheid — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J1561	1	10	10,390	$40	$394.6K
J9271	5	70	7,200	$40	$323.3K
J1745	17	60	1,540	$30	$76.7K
Q5115	1	10	2,070	$30	$67.8K
J0897	16	90	1,770	$20	$50.8K
J1439	2	10	45,750	$1	$40K
J2506	9	20	290	$80	$34.3K
J0881	15	20	10,680	$1	$25.4K
J9217	38	80	80	$130	$17.1K
96413	2	230	70	$100	$11.5K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Shari Germscheid, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Memorial Health Care	MN	Ambulance	$0	$112.8M
Fairview Health Services	MN	General Acute Care Hospital	$0	$90.4M
Regions Hospital	MN	General Acute Care Hospital	$0	$44.4M
Fairview Express Care	MN	Specialist	$0	$33.1M
North Memorial Health Care	MN	General Acute Care Hospital	$0	$32.5M
Fairview Health Services	MN	General Acute Care Hospital	$0	$30M
Mayo Clinic Health System-southwest Minnesota Region	MN	General Acute Care Hospital	$0	$28.5M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Fairview Health Services	MN	Emergency Medicine Physician	$0	$26.6M
Mayo Clinic Health System-southwest Minnesota Region	MN	Multi-Specialty Clinic/Center	$0	$24.3M

Nearby Providers

Other providers in the same ZIP code as Shari Germscheid, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Csl Rose Arbor	MN	Assisted Living Facility	$0	$7.9M
Smile Orthodontics Stillwater LLC	MN	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$4.4M
Natalie Huang	MN	Cardiovascular Disease Physician	$94.6K	$1.3K
Emily Chenoweth	MN	Occupational Therapist	$59.1K	$0

Shari Germscheid — Billing Profile & Reimbursement Data

Sign up for Shari Germscheid — Billing Profile & Reimbursement Data policy alerts

Shari Germscheid — Billing Profile & Reimbursement Data

Sign up for Shari Germscheid — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References